Multi-omics integration in malignant pleural mesothelioma: from molecular evolution and immune ecosystems to precision therapy

Our plain-English summary of Multi-omics integration in malignant pleural mesothelioma: from molecular evolution and immune ecosystems to precision therapy, by H. Li, K. Zhou, R. Xu, et al (Frontiers in Oncology, 2026).

The study

• Authors: H. Li, K. Zhou, R. Xu, W. Wang, T. Song, Y. Zhou, J. Ren, Z. Wang, Y. Liang, Y. Chen, S. Poudel, J. Yu, R. Lin, K. Yin, S. Yang, L. Zhuang
• Journal: Frontiers in Oncology
• Published: 2026;16:1883870
• Type of article: Review
• Read it: PubMed · Publisher · Free full text

Abstract

Malignant pleural mesothelioma (MPM) exhibits substantial molecular and cell-state heterogeneity, together with marked spatial variation in its immune and stromal microenvironment. Histological classification and individual biomarkers alone cannot adequately explain its evolution or heterogeneous treatment responses. This review critically integrates genomic, epigenomic, transcriptomic, single-cell, and spatial omics evidence along a conceptual continuum encompassing tumor-intrinsic molecular evolution, microenvironmental ecosystem remodeling, candidate stratification, and precision therapy. Current evidence indicates that alterations involving BAP1, CDKN2A/MTAP, and the NF2/Hippo pathway impose evolutionary constraints and create candidate therapeutic vulnerabilities but are insufficient to determine functional phenotypes independently. Epithelioid, uncommitted, and sarcomatoid malignant cell states may coexist within the same genetic clone, while immune and stromal features display pronounced regional heterogeneity. Based on published human MPM cohorts, we further propose four provisional immune-ecosystem archetypes: T-cell-inflamed, B-cell/tertiary lymphoid structure-organized, myeloid-dominant, and immune-desert. Tumor-intrinsic molecular states and stromal-spatial features are treated as interpretive modifiers. This literature-derived framework is intended for hypothesis generation and has not been developed or validated as a clinical classifier. At present, the principal value of multi-omics lies in mechanistic discovery and the design of biomarker-enriched clinical trials. Future studies should employ standardized assays in multicenter cohorts, independent external validation, formal archetype-by-treatment interaction testing within randomized trials, and longitudinal sampling to determine the treatment-predictive value and clinical feasibility of this framework.

Copyright © 2026 Li, Zhou, Xu, Wang, Song, Zhou, Ren, Wang, Liang, Chen, Poudel, Yu, Lin, Yin, Yang and Zhuang.

In plain English

This article was a review, not a new study of patients. The authors brought together published genomic, epigenomic, transcriptomic, single-cell and spatial ("multi-omics") research on malignant pleural mesothelioma (MPM). They noted that asbestos exposure remains the principal established risk factor for MPM, but the review focused on tumor biology rather than on exposure. Drawing on the studies they reviewed, the authors reported that changes in the genes BAP1 and CDKN2A/MTAP and in the NF2/Hippo pathway constrain how tumors evolve and point to candidate treatment targets. However, these changes do not on their own determine how tumors behave. They described evidence that epithelioid, "uncommitted" and sarcomatoid tumor-cell states can coexist within the same genetic clone. They also described evidence that immune and stromal features vary from region to region. From published human cohorts, the authors proposed four provisional immune "archetypes": T-cell-inflamed, B-cell/tertiary lymphoid structure-organized, myeloid-dominant and immune-desert. They stressed that this framework was not derived by reanalyzing patient data, has not been clinically validated, and is meant for generating hypotheses. The authors concluded that multi-omics currently serves mainly for mechanistic discovery and for designing biomarker-enriched trials.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: review (literature synthesis proposing a conceptual framework)
• Who was studied: No new patients were studied; the review drew on published human MPM cohorts and related genomic, single-cell, spatial and preclinical studies
• Exposure: Not an exposure study. The review states that asbestos exposure is the principal established risk factor for MPM. No fiber types or doses were analyzed.
• Main results:
  • From the literature reviewed: alterations in BAP1, CDKN2A/MTAP and the NF2/Hippo pathway impose evolutionary constraints and create candidate therapeutic vulnerabilities, but are insufficient to determine functional phenotypes independently
  • From a single-cell study the authors reviewed: epithelioid, uncommitted and sarcomatoid malignant cell states can coexist within the same genetic clone
  • From the studies reviewed: immune and stromal features of MPM show substantial spatial heterogeneity
  • The authors proposed four provisional immune-ecosystem archetypes: T-cell-inflamed, B-cell/TLS-organized, myeloid-dominant and immune-desert
  • The archetypes were a conceptual synthesis of published findings, not derived by reclustering patient-level data
  • The authors noted that no multi-omics classifier has been validated for routine treatment selection in MPM
• The authors' conclusion: The authors concluded that their literature-derived framework is hypothesis-generating rather than clinically validated. They also concluded that the main current value of multi-omics lies in mechanistic discovery and in the design of biomarker-enriched trials.
• Limitations the authors state:
  • The proposed archetypes are not clinically validated subtypes and lack standardized cross-platform thresholds
  • Individual tumors may show mixed or intermediate states
  • The proposed evolution model rests on predominantly cross-sectional evidence
  • The underlying studies are limited by small sample sizes

Topics

Medical terms in this study, explained in our Lexicon: Pleural Mesothelioma, Histological Subtype, Biomarker, BAP1, CDKN2A, MTAP, Epithelioid, Sarcomatoid.

Related studies

• Multi-omics integration reveals tumor and microenvironmental heterogeneity in malignant pleural mesothelioma — H. Hu, L. Li, et al. (2026)
• Evidence Based on an Integrative Analysis of Multi-Omics Data on METTL7A as a Molecular Marker in Pan-Cancer — Z. Liu, Y. Chen, et al. (2023)
• DNA methylation status classifies pleural mesothelioma cells according to their immune profile: implication for precision epigenetic therapy — M.F. Lofiego, R. Tufano, et al. (2025)
• A comprehensive investigation on pan-cancer impacts of constitutive centromere associated network gene family by integrating multi-omics data: A CONSORT-compliant article — H. Su, Y. Fan, et al. (2022)
• Exploring the Impact of DNA Methylation on Gene Expression in CRC: A Computational Approach for Identifying Epigenetically Regulated Genes in Multi-Omic Datasets — A.S. Blindu, S. Berardelli, et al. (2026)
• Multi-omics analysis positions DNA2 at the interface of genome integrity programs and tumor behavior in pan-cancer — D. Pandit, A. Dhillon, et al. (2026)

Browse more research in Frontiers in Oncology, or return to medical research.